Researchers at the university of Portland have told us that they are happy with RP-386 otherwise known as the super vaccine. Lead scientists say that subjects dosed are protected for a much longer duration, and they hope to have a yearly treatment plan developed soon. Several major pharmacological manufacturers are set to begin production once the senate approves the rush through the FDA red tape.
~Breaking news observed in session 4
No comments:
Post a Comment